GVM 2 Tablet SR is a combination oral hypoglycemic agent formulated to manage type 2 diabetes mellitus by improving glycemic control through complementary mechanisms. It contains Glimepiride 2mg, Metformin 500mg, and Voglibose 0.2mg. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glucose uptake in muscles and adipose tissue. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the intestine, minimizing postprandial hyperglycemia. The sustained-release (SR) formulation ensures gradual drug release, promoting steady plasma concentrations and improving patient compliance by reducing dosing frequency. GVM 2 Tablet SR is indicated for patients inadequately controlled on diet and exercise alone or those requiring combination therapy to achieve optimal glycemic targets. It should be used with caution in patients with renal or hepatic impairment, and regular monitoring of blood glucose and renal function is recommended. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort. This combination therapy offers a multifaceted approach to glycemic management, addressing fasting and postprandial glucose levels effectively.